Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “AQP4+ NMOSD”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Not applicableLooking for participantsNCT05966467
What this trial is testing

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

Who this might be right for
Neuromyelitis Optica Spectrum DisorderNMOSDAQP4+ NMOSD
Alexion Pharmaceuticals, Inc. 122
Large-scale testing (Phase 3)Active Not RecruitingNCT05403138
What this trial is testing

Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders

Who this might be right for
Neuromyelitis OpticaNeuromyelitis Optica Spectrum DisorderNMO Spectrum Disorder
Tianjin Medical University General Hospital 135
Early research (Phase 1)WithdrawnNCT03605238
What this trial is testing

Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20

Who this might be right for
Neuromyelitis Optica Spectrum Disorder
Chinese PLA General Hospital
Large-scale testing (Phase 3)Ended earlyNCT01892345
What this trial is testing

Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Who this might be right for
Neuromyelitis OpticaNeuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc. 143
Not applicableLooking for participantsNCT06885957
What this trial is testing

Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD

Who this might be right for
NMO Spectrum Disorder
Tongji Hospital 200
Not applicableActive Not RecruitingNCT06767020
What this trial is testing

Comparative Study on AQP4 Antibody Detection Methods

Who this might be right for
NMOSD
First Affiliated Hospital of Chongqing Medical University 120
Very early researchLooking for participantsNCT05145361
What this trial is testing

Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)

Who this might be right for
NMO Spectrum Disorder
Shanghai Pharmaceuticals Holding Co., Ltd 45
Not applicableStudy completedNCT06888622
What this trial is testing

BLAZE-Limiting Approach in NMOSD

Who this might be right for
Neuromyelitis Optica Spectrum Disorders (NMOSD)
Huashan Hospital 9
Early research (Phase 1)Not Yet RecruitingNCT06633042
What this trial is testing

The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD

Who this might be right for
Autoimmune Disease
Bioray Laboratories 18
Testing effectiveness (Phase 2)Looking for participantsNCT05504694
What this trial is testing

Ofatumumab in AQP4-IgG Seropositive NMOSD

Who this might be right for
Neuromyelitis Optica Spectrum Disorder
Tang-Du Hospital 5
Large-scale testing (Phase 3)Looking for participantsNCT05199688
What this trial is testing

Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Who this might be right for
Neuromyelitis Optica Spectrum DisorderNMOSD
Hoffmann-La Roche 8
Large-scale testing (Phase 3)Active Not RecruitingNCT06724809
What this trial is testing

Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD

Who this might be right for
NMOSDNeuromyelitis Optica Spectrum Disorders
Alexion Pharmaceuticals, Inc. 21
Not applicableNot Yet RecruitingNCT06903130
What this trial is testing

Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)

Who this might be right for
NMOSD
National and Kapodistrian University of Athens 40
Early research (Phase 1)Study completedNCT01777412
What this trial is testing

Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations

Who this might be right for
Neuromyelitis OpticaNeuromyelitis Optica Spectrum Disorder
Johns Hopkins University 10
Not applicableStudy completedNCT03766347
What this trial is testing

Pediatric NMOSD Observational Study

Who this might be right for
Neuromyelitis OpticaNMO Spectrum Disorder
Mayo Clinic 100
Large-scale testing (Phase 3)Looking for participantsNCT05346354
What this trial is testing

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

Who this might be right for
Neuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc. 12
Not applicableLooking for participantsNCT07247292
What this trial is testing

Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia

Who this might be right for
Rare DiseasesNeuromyelitis Optica Spectrum Disorder (NMOSD)
AstraZeneca 100